No evidence for interference of H&E staining in DNA testing: Usefulness of DNA extraction from H&E-stained archival tissue sections

American Journal of Clinical Pathology

Volumn 138, Issue 1, 2012, Pages 122-129

  Morikawa, Teppei ^a   Shima, Kaori ^a   Kuchiba, Aya ^a   Yamauchi, Mai ^a   Tanaka, Noriko ^a   Imamura, Yu ^a   Liao, Xiaoyun ^a   Qian, Zhi Rong ^a   Brahmandam, Mohan ^a   Longtine, Janina A ^b   Lindeman, Neal I ^b   Fuchs, Charles S ^a,b   Ogino, Shuji ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Histochemical staining; Microdissection; Molecular diagnostics; Mutation detection; Polymerase chain reaction; Solid tumor

Indexed keywords

B RAF KINASE; EOSIN; HEMATOXYLIN; K RAS PROTEIN; MICROSATELLITE DNA;

AGAR GEL ELECTROPHORESIS; ARTICLE; CANCER TISSUE; COLORECTAL CANCER; CONTROLLED STUDY; DNA DETERMINATION; DNA EXTRACTION; DNA FRAGMENTATION; DNA ISOLATION; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; MICROSATELLITE INSTABILITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; STAINING; TISSUE SECTION;

COLON; COLORECTAL NEOPLASMS; COLORING AGENTS; DNA, NEOPLASM; EOSINE YELLOWISH-(YS); HEMATOXYLIN; HUMANS; POLYMERASE CHAIN REACTION; RECTUM; STAINING AND LABELING;

EID: 84864222696     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP28LAOOKSZSVW     Document Type: Article

References (54)

1. Ausch C, Buxhofer-Ausch V, Oberkanins C, et al. Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization. J Mol Diagn. 2009;11:508-513.
2. Zheng S, Cummings OW, Saxena R, et al. Clonality and TP53 mutation analysis of focal nodular hyperplasia of the liver. Am J Clin Pathol. 2010;134:65-70.
3. Battochio A, Mohammed S, Winthrop D, et al. Detection of c-KIT and PDGFRA gene mutations in gastrointestinal stromal tumors: comparison of DHPLC and DNA sequencing methods using a single population-based cohort. Am J Clin Pathol. 2010;133:149-155.
4. Hostein I, Faur N, Primois C, et al. BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol. 2010;133:141-148.
5. Ross JS, Torres-Mora J, Wagle N, et al. Biomarker-based prediction of response to therapy for colorectal cancer: current perspective. Am J Clin Pathol. 2010;134:478-490.
6. Tsiatis AC, Norris-Kirby A, Rich RG, et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn. 2010;12:425-432.
7. Monzon FA, Ogino S, Hammond ME, et al. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med. 2009;133:1600-1606.
8. Shibata D, Hawes D, Li ZH, et al. Specific genetic analysis of microscopic tissue after selective ultraviolet radiation fractionation and the polymerase chain reaction. Am J Pathol. 1992;141:539-543.
9. Lukish JR, Muro K, DeNobile J, et al. Prognostic significance of DNA replication errors in young patients with colorectal cancer. Ann Surg. 1998;227:51-56. (Pubitemid 28071337)
10. Burton MP, Schneider BG, Brown R, et al. Comparison of histologic stains for use in PCR analysis of microdissected, paraffin-embedded tissues. Biotechniques. 1998;24:86-92. (Pubitemid 28079290)
11. Diss TC, Pan L, Peng H, et al. Sources of DNA for detecting B cell monoclonality using PCR. J Clin Pathol. 1994;47:493-496. (Pubitemid 24294007)
12. de Lang A, Wilander E. Sensitivity of HPV tests on stained vs unstained cervical smears. Acta Cytol. 2005;49:595-599. (Pubitemid 41667075)
13. Murase T, Inagaki H, Eimoto T. Influence of histochemical and immunohistochemical stains on polymerase chain reaction. Mod Pathol. 2000;13:147-151. (Pubitemid 30109101)
14. Rowe LR, Bentz BG, Bentz JS. Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis. J Clin Pathol. 2007;60:1211-1215. (Pubitemid 350084540)
15. van Puijenbroek M, Nielsen M, Tops CM, et al. Identification of patients with (atypical) MUTYH-associated polyposis by KRAS2 c.34G > T prescreening followed by MUTYH hotspot analysis in formalin-fixed paraffin-embedded tissue. Clin Cancer Res. 2008;14:139-142. (Pubitemid 351377988)
16. Kristensen LS, Wojdacz TK, Thestrup BB, et al. Quality assessment of DNA derived from up to 30 years old formalin fixed paraffin embedded (FFPE) tissue for PCR-based methylation analysis using SMART-MSP and MS-HRM. BMC Cancer. 2009;9:453. doi:10.1186/1471-2407-9-453.
17. Messick CA, Church JM, Liu X, et al. Stage III colorectal cancer: molecular disparity between primary cancers and lymph node metastases. Ann Surg Oncol. 2010;17:425-431.
18. Morikawa T, Kuchiba A, Yamauchi M, et al. Association of CTNNB1 (β-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA. 2011;305:1685-1694.
19. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356:2131-2142. (Pubitemid 47010839)
20. Nosho K, Irahara N, Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One. 2008;3:e3698. doi:10.1371/journal.pone. 0003698.
21. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn. 2005;7:413-421. (Pubitemid 41149657)
22. Ogino S, Kawasaki T, Kirkner GJ, et al. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn. 2006;8:582-588. (Pubitemid 44774157)
23. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753-762.
24. Figueiredo JC, Grau MV, Wallace K, et al. Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors. Cancer Epidemiol Biomarkers Prev. 2009;18:1041-1049.
25. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009;69:1851-1857.
26. Barault L, Charon-Barra C, Jooste V, et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res. 2008;68:8541-8546.
27. Zlobec I, Bihl M, Foerster A, et al. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. J Pathol. 2011;225:336-343.
28. Samowitz WS, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology. 2005;129:837-845. (Pubitemid 41242676)
29. Hughes LA, Simons CC, van den Brandt PA, et al. Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP). PLoS One. 2011;6:e18571. doi:10.1371/journal.pone.0018571.
30. Limsui D, Vierkant RA, Tillmans LS, et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst. 2010;102:1012-1022.
31. Rozek LS, Herron CM, Greenson JK, et al. Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2010;19:838-843.
32. Brink M, de Goeij AF, Weijenberg MP, et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis. 2003;24:703-710. (Pubitemid 36592405)
33. English DR, Young JP, Simpson JA, et al. Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev. 2008;17:1774-1780.
34. Chen JT, Lane MA, Clark DP. Inhibitors of the polymerase chain reaction in Papanicolaou stain: removal with a simple destaining procedure. Acta Cytol. 1996;40:873-877. (Pubitemid 26322335)
35. Uhlmann K, Brinckmann A, Toliat MR, et al. Evaluation of a potential epigenetic biomarker by quantitative methyl-single nucleotide polymorphism analysis. Electrophoresis. 2002;23:4072-4079. (Pubitemid 36131460)
36. Jordan JA, Butchko AR, Durso MB. Use of pyrosequencing of 16S rRNA fragments to differentiate between bacteria responsible for neonatal sepsis. J Mol Diagn. 2005;7:105-110. (Pubitemid 40310172)
37. Garcia CA, Ahmadian A, Gharizadeh B, et al. Mutation detection by pyrosequencing: sequencing of exons 5-8 of the p53 tumor suppressor gene. Gene. 2000;253:249-257. (Pubitemid 30625216)
38. Nosho K, Kawasaki T, Ohnishi M, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia. 2008;10:534-541. (Pubitemid 351770297)
39. Colella S, Shen L, Baggerly KA, et al. Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites. Biotechniques. 2003;35:146-150. (Pubitemid 36828724)
40. Mikeska T, Bock C, El-Maarri O, et al. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn. 2007;9:368-381. (Pubitemid 47305073)
41. Irahara N, Nosho K, Baba Y, et al. Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells. J Mol Diagn. 2010;12:177-183.
42. Ogino S, Chan AT, Fuchs CS, et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut. 2011;60:397-411.
43. Earle JS, Luthra R, Romans A, et al. Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J Mol Diagn. 2010;12:433-440.
44. de la Chapelle A, Hampel H. Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol. 2010;28:3380-3387.
45. Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut. 2011;60:116-129.
46. Murphy KM, Berg KD, Geiger T, et al. Capillary electrophoresis artifact due to eosin: implications for the interpretation of molecular diagnostic assays. J Mol Diagn. 2005;7:143-148. (Pubitemid 40310178)
47. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96:8681-8686. (Pubitemid 29354851)
48. Hinoue T, Weisenberger DJ, Lange CP, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2012;22:271-282. doi:10.1101/gr.117523.110.
49. Tanaka N, Huttenhower C, Nosho K, et al. Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer. Am J Pathol. 2010;177:2731-2740.
50. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol. 2011;8:686-700.
51. Hughes LA, Khalid-de Bakker CA, Smits KM, et al. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim Biophys Acta. 2011;1825:77-85.
52. Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: past, present and future. Patholog Res Int. 2011;2011:902674. doi:10.4061/2011/902674.
53. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009;58:90-96.
54. Ogino S, Galon J, Fuchs CS, et al. Cancer immunology: analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol. 2011;8:711-719.